SCHEMBL21943519

SCHEMBL21943519

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Oc1cc(-c2ccncc2)nc2c1ccn2C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.54
▸ KIT P10721 3/20 0.54
▸ PDGFRB P09619 1/20 0.54
▸ DDR1 Q08345 1/20 0.54
▸ BRAF P15056 8/20 0.54
▸ TEK Q02763 6/20 0.52
▸ KDR P35968 5/20 0.52
▸ PIKFYVE Q9Y2I7 1/20 0.48
▸ POLB P06746 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ABL1 P00519 3/20 0.47
▸ LCK P06239 2/20 0.47
▸ SRC P12931 2/20 0.47
▸ MAPK14 Q16539 2/20 0.47
▸ YES1 P07947 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ TPX2 Q9ULW0 1/20 0.47
▸ RAF1 P04049 1/20 0.46
▸ BCR P11274 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943451 0.94 KDR (0.58) CSF1RKITPDGFRBDDR1BRAF
SCHEMBL21943517 0.92 TEK (0.57) CSF1RKITPDGFRBDDR1BRAF
SCHEMBL21943450 0.89 BRAF (0.51) KITPDGFRBBRAFTEKKDR
SCHEMBL21943069 0.87 KDR (0.51) KITPDGFRBBRAFTEKKDR
SCHEMBL21943657 0.87 BRAF (0.53) CSF1RKITPDGFRBDDR1BRAF
SCHEMBL22024557 0.87 PIKFYVE (0.61) CSF1RKITPDGFRBDDR1BRAF
SCHEMBL21943534 0.86 KDR (0.58) CSF1RKITPDGFRBDDR1BRAF
SCHEMBL21943518 0.85 PIKFYVE (0.64) CSF1RKITPDGFRBDDR1BRAF
SCHEMBL21943452 0.84 KDR (0.47) CSF1RKITPDGFRBBRAFTEK
SCHEMBL22065428 0.82 POLB (0.58) CSF1RKITPDGFRBDDR1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 — — US disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 CSF1R 3749/4885KIT 603/4885PDGFRB 1488/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 CSF1R 3749/4885KIT 603/4885PDGFRB 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback